There is developing data for the use of low-dose intravenous alteplase (0.6mg/kg body
weight; maximum 60 mg) compared to standard-dose alteplase (0.9mg/kg body weight;
maximum 90 mg), however much of this data has been conflicting, especially across
different patient populations. In the recently completed alteplase-dose evaluation
arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (Enchanted),
low-dose alteplase was not shown to meet the noninferiority margin defined by the
modified Rankin score (mRS) compared to standard-dose alteplase. However, this initial
arm did not evaluate the use of low-dose alteplase in specific populations which may
benefit from the reduced risk of symptomatic intracerebral hemorrhage (sICH).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
